Cargando…

Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans

BACKGROUND: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. The interleukin-6 (IL-6) receptor antagonist tocilizumab has been shown to lower serum Lp(a) concentrations. We investigated whether the IL-6 single nucleotide polymorphism −174G/C is associated with baselin...

Descripción completa

Detalles Bibliográficos
Autores principales: Berthold, Heiner K., Laudes, Matthias, Krone, Wilhelm, Gouni-Berthold, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173458/
https://www.ncbi.nlm.nih.gov/pubmed/21935443
http://dx.doi.org/10.1371/journal.pone.0024719
_version_ 1782211963612299264
author Berthold, Heiner K.
Laudes, Matthias
Krone, Wilhelm
Gouni-Berthold, Ioanna
author_facet Berthold, Heiner K.
Laudes, Matthias
Krone, Wilhelm
Gouni-Berthold, Ioanna
author_sort Berthold, Heiner K.
collection PubMed
description BACKGROUND: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. The interleukin-6 (IL-6) receptor antagonist tocilizumab has been shown to lower serum Lp(a) concentrations. We investigated whether the IL-6 single nucleotide polymorphism −174G/C is associated with baseline serum Lp(a) concentrations. METHODOLOGY/PRINCIPAL FINDINGS: We divided 2321 subjects from the Lipid Analytic Cologne (LIANCO) cohort into 2 groups, the ones with substantially elevated Lp(a), defined as concentrations ≥60 mg/dl (n = 510), and the ones with Lp(a) <60 mg/dl (n = 1811). The association with the genotypes GG (33.7%), GC (50.75%) and CC (15.55%) was investigated. The GC and the CC genotype were associated with a significantly increased odds ratio of having substantially elevated Lp(a) concentrations (OR = 1.3, 95% CI 1.04 to 1.63, P = 0.02 and OR = 1.44, 95% CI 1.06 to 1.93, P = 0.018). These associations remained significant after adjusting for age, sex, smoking behavior, body mass index, serum lipoproteins, hypertension and diabetes. Of these covariates, only LDL cholesterol was significantly and independently associated with elevated Lp(a) concentrations. CONCLUSIONS/SIGNIFICANCE: The IL-6 single nucleotide polymorphism −174G/C is associated with increased odds of having elevated Lp(a). Whether this association plays a role in the Lp(a)-lowering effects of IL-6 receptor antagonists remains to be established.
format Online
Article
Text
id pubmed-3173458
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31734582011-09-20 Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans Berthold, Heiner K. Laudes, Matthias Krone, Wilhelm Gouni-Berthold, Ioanna PLoS One Research Article BACKGROUND: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. The interleukin-6 (IL-6) receptor antagonist tocilizumab has been shown to lower serum Lp(a) concentrations. We investigated whether the IL-6 single nucleotide polymorphism −174G/C is associated with baseline serum Lp(a) concentrations. METHODOLOGY/PRINCIPAL FINDINGS: We divided 2321 subjects from the Lipid Analytic Cologne (LIANCO) cohort into 2 groups, the ones with substantially elevated Lp(a), defined as concentrations ≥60 mg/dl (n = 510), and the ones with Lp(a) <60 mg/dl (n = 1811). The association with the genotypes GG (33.7%), GC (50.75%) and CC (15.55%) was investigated. The GC and the CC genotype were associated with a significantly increased odds ratio of having substantially elevated Lp(a) concentrations (OR = 1.3, 95% CI 1.04 to 1.63, P = 0.02 and OR = 1.44, 95% CI 1.06 to 1.93, P = 0.018). These associations remained significant after adjusting for age, sex, smoking behavior, body mass index, serum lipoproteins, hypertension and diabetes. Of these covariates, only LDL cholesterol was significantly and independently associated with elevated Lp(a) concentrations. CONCLUSIONS/SIGNIFICANCE: The IL-6 single nucleotide polymorphism −174G/C is associated with increased odds of having elevated Lp(a). Whether this association plays a role in the Lp(a)-lowering effects of IL-6 receptor antagonists remains to be established. Public Library of Science 2011-09-14 /pmc/articles/PMC3173458/ /pubmed/21935443 http://dx.doi.org/10.1371/journal.pone.0024719 Text en Berthold et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Berthold, Heiner K.
Laudes, Matthias
Krone, Wilhelm
Gouni-Berthold, Ioanna
Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title_full Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title_fullStr Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title_full_unstemmed Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title_short Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
title_sort association between the interleukin-6 promoter polymorphism −174g/c and serum lipoprotein(a) concentrations in humans
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173458/
https://www.ncbi.nlm.nih.gov/pubmed/21935443
http://dx.doi.org/10.1371/journal.pone.0024719
work_keys_str_mv AT bertholdheinerk associationbetweentheinterleukin6promoterpolymorphism174gcandserumlipoproteinaconcentrationsinhumans
AT laudesmatthias associationbetweentheinterleukin6promoterpolymorphism174gcandserumlipoproteinaconcentrationsinhumans
AT kronewilhelm associationbetweentheinterleukin6promoterpolymorphism174gcandserumlipoproteinaconcentrationsinhumans
AT gounibertholdioanna associationbetweentheinterleukin6promoterpolymorphism174gcandserumlipoproteinaconcentrationsinhumans